Ethical perspectives on RNA interference therapeutics

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Ethical perspectives on RNA interference therapeutics. / Ebbesen, Mette; Jensen, Thomas G.; Andersen, Svend; Pedersen, Finn Skou.

I: International Journal of Medical Sciences, Bind 5, Nr. 3, 2008, s. 159-68.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Ebbesen, M, Jensen, TG, Andersen, S & Pedersen, FS 2008, 'Ethical perspectives on RNA interference therapeutics', International Journal of Medical Sciences, bind 5, nr. 3, s. 159-68.

APA

CBE

MLA

Ebbesen, Mette o.a.. "Ethical perspectives on RNA interference therapeutics". International Journal of Medical Sciences. 2008, 5(3). 159-68.

Vancouver

Author

Bibtex

@article{8172d5300c1411dfb95d000ea68e967b,
title = "Ethical perspectives on RNA interference therapeutics",
abstract = "RNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of principles of the American bioethicists, Tom L. Beauchamp and James F. Childress.",
keywords = "Animals, Bioethics, Cell Line, Tumor, Clinical Trials as Topic, Disease Models, Animal, Drug Design, Ethics, Research, Gene Silencing, Gene Therapy, Genetic Techniques, Humans, Mice, Mice, SCID, RNA Interference, Risk",
author = "Mette Ebbesen and Jensen, {Thomas G.} and Svend Andersen and Pedersen, {Finn Skou}",
year = "2008",
language = "English",
volume = "5",
pages = "159--68",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "3",

}

RIS

TY - JOUR

T1 - Ethical perspectives on RNA interference therapeutics

AU - Ebbesen, Mette

AU - Jensen, Thomas G.

AU - Andersen, Svend

AU - Pedersen, Finn Skou

PY - 2008

Y1 - 2008

N2 - RNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of principles of the American bioethicists, Tom L. Beauchamp and James F. Childress.

AB - RNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of principles of the American bioethicists, Tom L. Beauchamp and James F. Childress.

KW - Animals

KW - Bioethics

KW - Cell Line, Tumor

KW - Clinical Trials as Topic

KW - Disease Models, Animal

KW - Drug Design

KW - Ethics, Research

KW - Gene Silencing

KW - Gene Therapy

KW - Genetic Techniques

KW - Humans

KW - Mice

KW - Mice, SCID

KW - RNA Interference

KW - Risk

M3 - Journal article

C2 - 18612370

VL - 5

SP - 159

EP - 168

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 3

ER -